MCID: SKL003
MIFTS: 39

Skeletal Muscle Cancer malady

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Skeletal Muscle Cancer

Aliases & Descriptions for Skeletal Muscle Cancer:

Name: Skeletal Muscle Cancer 12 14
Skeletal Muscle Neoplasm 12 14 69
Malignant Tumor of Skeletal Muscle 12
Tumor of Skeletal Muscle 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4043 DOID:4044
NCIt 47 C6516 C6514
SNOMED-CT 64 699955004

Summaries for Skeletal Muscle Cancer

MalaCards based summary : Skeletal Muscle Cancer, also known as skeletal muscle neoplasm, is related to rhabdomyosarcoma and neu-laxova syndrome 2. An important gene associated with Skeletal Muscle Cancer is MYOD1 (Myogenic Differentiation 1), and among its related pathways/superpathways are Developmental Biology and Transcriptional misregulation in cancer. The drugs Benzocaine and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, and related phenotypes are growth/size/body region and cellular

Related Diseases for Skeletal Muscle Cancer

Diseases related to Skeletal Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)
id Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 10.7
2 neu-laxova syndrome 2 10.2 MYF6 MYOD1
3 lung benign neoplasm 10.2 IGF1R IGF2 MYOD1
4 subacute leukemia 10.2 MB MYOG
5 verruciform xanthoma of skin 10.2 MB MYOD1
6 acantholytic squamous cell skin carcinoma 10.2 IGF2 MB
7 mixed type rhabdomyosarcoma 10.2 MB MYOD1 MYOG
8 brain stem infarction 10.2 MB MYOD1 MYOG
9 bile duct rhabdomyosarcoma 10.2 MB MYOD1 PAX3 PAX7
10 myoblastoma 10.2 MYF6 MYOD1 PAX3 PAX7
11 intrahepatic bile duct cystadenoma 10.2 MB MYOD1
12 pulmonary immaturity 10.2 CDK4 MB MYOD1
13 amelogenesis imperfecta-gingival hyperplasia syndrome 10.2 CDK4 MYOD1 MYOG
14 childhood medulloblastoma 10.2 MB MYOD1 MYOG
15 hormone producing pituitary cancer 10.2 CDK4 MYOD1 MYOG
16 enchondromatosis dwarfism deafness 10.1 CDK4 MYOD1 MYOG
17 congenital myasthenic syndrome 19 10.1 IGF2 MEF2A MEF2C MYOD1
18 palmoplantar keratosis 10.1 CDK4 MB MYOG
19 adenosarcoma 10.1 CDK4 IGF2 MB MYOG
20 cerebral cavernous malformations-2 10.0 IGF1R IGF2 MYOD1 MYOG
21 testis sarcoma 10.0 MYOD1 MYOG
22 advanced sleep-phase syndrome, familial, 2 9.9 MB MYF6 MYOD1 TFE3
23 kidney sarcoma 9.9 KIDINS220 MYF5 MYF6 MYOD1 MYOG
24 collecting duct carcinoma 9.9 FOXO1 PAX3 TFE3
25 prostate rhabdomyosarcoma 9.8 CDK4 IGF2 MB MYOD1 MYOG PAX3
26 spindle cell rhabdomyosarcoma 9.8 FOXO1 MB MYF5 MYOD1 MYOG PAX3
27 lipoma 9.6
28 muscle cancer 9.6
29 rhabdomyosarcoma 2, alveolar 9.5 CDK4 FOXO1 IGF1R KIDINS220 MB MYOD1
30 embryonal extrahepatic bile duct rhabdomyosarcoma 9.3 CDK4 FOXO1 IGF1R IGF2 MB MYF5
31 mediastinum sarcoma 9.3 FOXO1 IGF2 KIDINS220 MB MYOD1 MYOG
32 mediastinum rhabdomyosarcoma 7.9 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2

Graphical network of the top 20 diseases related to Skeletal Muscle Cancer:



Diseases related to Skeletal Muscle Cancer

Symptoms & Phenotypes for Skeletal Muscle Cancer

MGI Mouse Phenotypes related to Skeletal Muscle Cancer:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 CDK4 CDKN1A FOXO1 IGF1R IGF2 KIDINS220
2 cellular MP:0005384 10.45 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2
3 cardiovascular system MP:0005385 10.4 MB MEF2A MEF2C MYOD1 NACA PAX3
4 homeostasis/metabolism MP:0005376 10.39 FOXO1 IGF1R IGF2 JDP2 MB MYF5
5 mortality/aging MP:0010768 10.39 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
6 behavior/neurological MP:0005386 10.37 CDKN1A FOXO1 IGF1R IGF2 MEF2A MEF2C
7 embryo MP:0005380 10.36 CDK4 CDKN1A FOXO1 IGF1R IGF2 MB
8 muscle MP:0005369 10.31 MYOG NACA PAX3 PAX7 TFAP2B CDK4
9 hematopoietic system MP:0005397 10.3 PAX7 RHD TFE3 CDK4 CDKN1A FOXO1
10 immune system MP:0005387 10.24 IGF1R IGF2 JDP2 MEF2C MYF5 PAX3
11 craniofacial MP:0005382 10.22 CDKN1A FOXO1 IGF1R IGF2 MEF2C MYF5
12 adipose tissue MP:0005375 10.2 MYOD1 MYOG CDKN1A FOXO1 IGF1R JDP2
13 integument MP:0010771 10.18 CDK4 CDKN1A FOXO1 IGF1R IGF2 JDP2
14 digestive/alimentary MP:0005381 10.1 CDK4 CDKN1A FOXO1 IGF1R IGF2 PAX3
15 normal MP:0002873 10.07 MEF2C MYF5 MYF6 MYOD1 MYOG NACA
16 limbs/digits/tail MP:0005371 10.06 CDKN1A FOXO1 IGF1R IGF2 JDP2 MEF2C
17 neoplasm MP:0002006 10.02 CDK4 CDKN1A FOXO1 IGF1R MYF5 MYF6
18 no phenotypic analysis MP:0003012 10.02 CDKN1A FOXO1 IGF2 KIDINS220 MYF5 MYF6
19 respiratory system MP:0005388 9.97 MYF5 MYF6 MYOD1 MYOG PAX3 PAX7
20 skeleton MP:0005390 9.8 MYOG NACA PAX3 PAX7 TFE3 CDKN1A
21 vision/eye MP:0005391 9.28 CDK4 CDKN1A IGF2 KIDINS220 MYF5 MYF6

Drugs & Therapeutics for Skeletal Muscle Cancer

Drugs for Skeletal Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
2
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
5 tannic acid Approved, Nutraceutical Phase 4
6 Analgesics Phase 4
7 Neuromuscular Agents Phase 4
8 Neuromuscular Blocking Agents Phase 4
9 Neuromuscular Nondepolarizing Agents Phase 4
10 Peripheral Nervous System Agents Phase 4,Phase 2
11 insulin Phase 4,Phase 3,Phase 2
12 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
13 2,4-thiazolidinedione Phase 4
14 HIV Protease Inhibitors Phase 4
15 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Matrix Metalloproteinase Inhibitors Phase 4
17
protease inhibitors Phase 4
18 TIMP1 protein, human Phase 4
19 TIMP3 protein, human Phase 4
20 Tissue Inhibitor of Metalloproteinase-1 Phase 4
21 Tissue Inhibitor of Metalloproteinase-3 Phase 4
22 Tissue Inhibitor of Metalloproteinases Phase 4
23 Hormone Antagonists Phase 4,Phase 3,Phase 2
24 Hormones Phase 4,Phase 3,Phase 2
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
27 Estrogens Phase 4
28 Dipeptidyl-Peptidase IV Inhibitors Phase 4
29 Incretins Phase 4
30 Sitagliptin Phosphate Phase 4
31 Aromatase Inhibitors Phase 4
32 Estrogen Antagonists Phase 4
33 Steroid Synthesis Inhibitors Phase 4
34 glutamine Nutraceutical Phase 4
35
Metformin Approved Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
36
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
37
Calcitriol Approved, Nutraceutical Phase 3,Phase 2 32222-06-3 134070 5280453
38
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
39 glucocorticoids Phase 3,Phase 2
40 Androgens Phase 3
41 Bone Density Conservation Agents Phase 3,Phase 2
42 Calcium, Dietary Phase 3,Phase 2
43 Micronutrients Phase 3,Phase 2
44 Trace Elements Phase 3,Phase 2
45 Vasoconstrictor Agents Phase 3,Phase 2
46 Vitamins Phase 3,Phase 2
47 Anti-Inflammatory Agents Phase 3,Phase 2
48 Antimitotic Agents Phase 3,Phase 1
49 Pharmaceutical Solutions Phase 3
50
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 106)
id Name Status NCT ID Phase
1 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4
2 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4
3 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Recruiting NCT01552291 Phase 4
4 Sitagliptin and Brown Adipose Tissue Recruiting NCT02294084 Phase 4
5 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4
6 Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose Completed NCT01775176 Phase 3
7 A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease Completed NCT00158600 Phase 3
8 Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Active, not recruiting NCT01308567 Phase 3
9 DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) Terminated NCT00273338 Phase 3
10 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2
11 Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II Completed NCT01694602 Phase 2
12 Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training Completed NCT00196885 Phase 2
13 Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients Completed NCT02930876 Phase 2
14 Calcitriol, Physical Activity, and Bone Health in Cancer Survivors Completed NCT00904033 Phase 2
15 Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons Completed NCT00935610 Phase 2
16 A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Completed NCT00401388 Phase 2
17 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors Recruiting NCT02739620 Phase 1, Phase 2
18 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Recruiting NCT02433197 Phase 1, Phase 2
19 OptiTrain - Optimal Training Women With Breast Cancer Recruiting NCT02522260 Phase 1, Phase 2
20 Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02776124 Phase 2
21 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction Recruiting NCT02918552 Phase 2
22 Acupuncture or Metformin for Insulin Resistance in Women With PCOS Recruiting NCT02647827 Phase 2
23 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Not yet recruiting NCT03111810 Phase 2
24 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1
25 Nutritional and Contractile Regulation of Muscle Growth Completed NCT00891696 Phase 1
26 Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma Completed NCT00003081 Phase 1
27 Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Recruiting NCT02106871 Phase 1
28 A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients Recruiting NCT03165955 Phase 1
29 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1
30 Role of Activin A (ActA) in the Human Cancer Cachexia Unknown status NCT01604642
31 Physiotherapy in Hematopoietic Stem Cell Transplantation Unknown status NCT02193399
32 Inflammation and Exercise in Stroke Unknown status NCT00891514
33 Effects of High Intensity Interval Training and Strength Training in Obese Unknown status NCT02484235
34 Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study Unknown status NCT01384123
35 Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients Completed NCT00446888
36 Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients Completed NCT00994669
37 Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss Completed NCT00899158
38 Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients Completed NCT01015274
39 Assessment of in Vivo Skeletal Muscle Viscoelasticity (ARFI Imaging) With Aging and Cancer Completed NCT01484821
40 Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery Completed NCT01667237 Early Phase 1
41 Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients Completed NCT01136083
42 Improving Muscle for Functional Independence Trial Completed NCT01049698
43 Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States Completed NCT00461240
44 Fish Oil Supplement in Rectal Cancer Completed NCT02534389
45 Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia Completed NCT02116166
46 NAC Supplementation and Skeletal Muscle Performance Completed NCT01778309
47 Green Tea, High in Epigallocatechin Gallate (EGCG) and Postprandial Fat Oxidation Completed NCT00867555
48 Time Course and Nature of Nutrient Sensing During Fasting in Humans Completed NCT01387919
49 Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients Completed NCT02571088
50 Cold Therapy in the Treatment of Exercise-induced Muscle Damage Completed NCT02341612

Search NIH Clinical Center for Skeletal Muscle Cancer

Genetic Tests for Skeletal Muscle Cancer

Anatomical Context for Skeletal Muscle Cancer

MalaCards organs/tissues related to Skeletal Muscle Cancer:

39
Skeletal Muscle

Publications for Skeletal Muscle Cancer

Articles related to Skeletal Muscle Cancer:

id Title Authors Year
1
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
2010

Variations for Skeletal Muscle Cancer

Expression for Skeletal Muscle Cancer

Search GEO for disease gene expression data for Skeletal Muscle Cancer.

Pathways for Skeletal Muscle Cancer

Pathways related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 CDK4 FOXO1 MEF2A MEF2C MYF5 MYF6
2 12.06 CDKN1A FOXO1 IGF1R MEF2C PAX3 PAX7
3
Show member pathways
12.03 CDK4 CDKN1A FOXO1 IGF1R
4 11.88 CDKN1A FOXO1 MEF2A MEF2C
5 11.85 CDK4 CDKN1A FOXO1 IGF1R IGF2
6 11.83 MEF2C MYF5 MYOD1 MYOG PAX3 PAX7
7 11.76 PAX3 PAX7 TFAP2B
8 11.74 FOXO1 MEF2C MYOD1
9 11.62 CDKN1A MYF6 MYOD1
10 11.52 CDK4 CDKN1A FOXO1 MEF2C MYOD1 TFE3
11 11.51 IGF1R IGF2 MEF2C
12 11.48 CDKN1A MEF2C MYOD1 PAX3
13
Show member pathways
11.37 CDKN1A IGF1R IGF2 MEF2A MEF2C MYF6
14 11.28 MEF2A MEF2C MYF5 MYOD1 PAX7
15 11.26 CDKN1A FOXO1 MYOD1
16 11.23 MEF2A MEF2C MYOD1
17
Show member pathways
11.2 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
18 10.67 MEF2A MEF2C

GO Terms for Skeletal Muscle Cancer

Cellular components related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 CDK4 CDKN1A FOXO1 JDP2 MEF2A MEF2C
2 transcription factor complex GO:0005667 9.46 CDK4 MEF2A MYOD1 MYOG
3 nucleoplasm GO:0005654 9.4 CDK4 CDKN1A FOXO1 MEF2A MEF2C MYF5
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.26 CDK4 CDKN1A

Biological processes related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 skeletal muscle cell differentiation GO:0035914 9.83 MEF2C MYF5 MYF6 MYOD1 MYOG
2 skeletal muscle tissue regeneration GO:0043403 9.81 MYF6 MYOG NACA PAX7
3 positive regulation of myoblast fusion GO:1901741 9.8 MYF5 MYF6 MYOD1 MYOG
4 ossification GO:0001503 9.78 IGF2 MYF5 MYOG
5 insulin receptor signaling pathway GO:0008286 9.77 FOXO1 IGF1R IGF2
6 myotube differentiation GO:0014902 9.75 MEF2C MYOD1 MYOG
7 muscle tissue morphogenesis GO:0060415 9.72 MYF5 MYF6 PAX7
8 positive regulation of skeletal muscle fiber development GO:0048743 9.67 MYF5 MYF6 MYOD1 MYOG
9 positive regulation of myoblast differentiation GO:0045663 9.65 MEF2C MYF5 MYF6 MYOD1 MYOG
10 skeletal muscle tissue development GO:0007519 9.63 MEF2C MYF5 MYF6 MYOD1 MYOG PAX7
11 myoblast differentiation GO:0045445 9.62 MYOD1 MYOG
12 muscle cell fate commitment GO:0042693 9.62 MYF5 MYF6 MYOD1 MYOG
13 response to hyperoxia GO:0055093 9.61 CDK4 CDKN1A
14 positive regulation of muscle cell differentiation GO:0051149 9.43 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
15 muscle organ development GO:0007517 9.23 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
16 transcription, DNA-templated GO:0006351 10.34 FOXO1 JDP2 MEF2A MEF2C MYF5 MYOD1
17 regulation of transcription, DNA-templated GO:0006355 10.32 FOXO1 IGF2 JDP2 MEF2A MEF2C MYF5
18 multicellular organism development GO:0007275 10.22 CDK4 IGF2 MEF2A MEF2C MYF5 MYF6
19 transcription from RNA polymerase II promoter GO:0006366 10.14 MEF2A MEF2C MYF5 MYF6 MYOD1 PAX3
20 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.14 FOXO1 MEF2A MEF2C MYF5 MYF6 MYOD1
21 cell differentiation GO:0030154 10.13 FOXO1 MEF2A MEF2C MYF5 MYF6 MYOD1
22 regulation of transcription from RNA polymerase II promoter GO:0006357 10.11 CDKN1A FOXO1 JDP2 MYF5 MYF6 MYOD1
23 positive regulation of transcription, DNA-templated GO:0045893 10.11 FOXO1 MEF2A MEF2C MYF6 MYOD1 MYOG
24 negative regulation of apoptotic process GO:0043066 10 CDKN1A FOXO1 IGF1R PAX7 TFAP2B

Molecular functions related to Skeletal Muscle Cancer according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.97 JDP2 MEF2A MEF2C MYF5 MYF6 MYOD1
2 chromatin binding GO:0003682 9.95 FOXO1 JDP2 MEF2A MEF2C MYOD1 TFAP2B
3 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.92 JDP2 MEF2A MEF2C MYF5 MYF6 MYOD1
4 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.89 MEF2A MEF2C MYOG TFAP2B TFE3
5 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.84 FOXO1 MEF2A MEF2C TFAP2B
6 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.83 MEF2A MEF2C MYOD1 MYOG
7 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.81 MYF5 MYF6 MYOD1 MYOG
8 E-box binding GO:0070888 9.71 MYF5 MYF6 MYOD1 MYOG
9 sequence-specific DNA binding GO:0043565 9.65 FOXO1 JDP2 MEF2A MEF2C MYF5 MYOD1
10 transcription factor activity, RNA polymerase II core promoter sequence-specific GO:0000983 9.63 MEF2C PAX7 TFAP2B
11 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.63 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
12 HMG box domain binding GO:0071837 9.56 MEF2C PAX3
13 core promoter proximal region sequence-specific DNA binding GO:0000987 9.55 MEF2C MYOG
14 protein dimerization activity GO:0046983 9.23 MEF2A MEF2C MYF5 MYF6 MYOD1 MYOG
15 DNA binding GO:0003677 10.21 FOXO1 JDP2 MEF2A MEF2C MYF5 MYF6
16 transcription factor activity, sequence-specific DNA binding GO:0003700 10 FOXO1 JDP2 MEF2A MEF2C MYF6 MYOD1

Sources for Skeletal Muscle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....